⌕
Viking Therapeutics · VKTX · Nasdaq
Tenet 36 · Weak
Compare
$26.88+0.30%At closeTenet 36 · Weak
$26.88+0.08 (+0.30%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Viking Therapeutics (VKTX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is VKTX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Fool - Investing NewsNov 17, 2026 · 00:09 ET
Viking: 3 Key Takeaways for Long-Term Investors

Dosing flexibility across weekly, biweekly, and monthly schedules gives Viking a structural advantage that currently approved competitors don't yet offer.…

VKTX +0.3% todayRead at source ↗
● PRNewsWireNov 15, 2026 · 12:05 ETCOMPANY'S OWN WORDS
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026

VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 Weeks VK2735 Treatment Led to Improvement Across Multiple Cardiometabolic Markers SAN DIEGO, Nov. 15…

VKTX +0.3% todayRead at source ↗
● Zacks Investment ResearchNov 13, 2026 · 10:16 ET
4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day

LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.…

VKTX +0.3% todayRead at source ↗
● The Motley FoolNov 13, 2026 · 04:15 ET
Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028

Viking's oral phase 3 obesity trial is key to expanding its addressable market and securing a favorable market share. Peak sales and valuation projections need to be based on risk-adjusted scenarios.…

VKTX +0.3% todayRead at source ↗
● The Motley FoolNov 11, 2026 · 17:34 ETEARNINGS EXPECTED BY FEB 16
Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?

Eli Lilly is one of the undisputed leaders in the weight loss market, and its progress in this area is helping it deliver excellent financial results. However, Viking Therapeutics, a smaller company, is also looking to m…

VKTX +0.3% todayRead at source ↗
● FXEmpireNov 11, 2026 · 16:41 ET
Viking Therapeutics (VKTX) Price Forecast: Bullish Reversal Targets $43.55

Viking Therapeutics is showing early signs of a bullish reversal, with improving momentum and key support potentially setting up a recovery toward a major consolidation breakout.…

VKTX +0.3% todayRead at source ↗
● PRNewsWireNov 9, 2026 · 07:05 ETCOMPANY'S OWN WORDS
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026

Poster Presentations Highlight Baseline Characteristics from the Phase 3 VANQUISH-2 Trial of Subcutaneous VK2735 and the Impact of VK2735 on Obesity Severity and Cardiometabolic Parameters in the Phase 2 VENTURE Study SA…

VKTX +0.3% todayRead at source ↗
● The Motley FoolNov 5, 2026 · 11:30 ETEARNINGS EXPECTED BY FEB 16
Here's the 1 Stock I'd Most Want to Buy If the Market Crashes

Viking's ongoing phase 3 trials are the key to unlocking value for shareholders. Its lead drug, VK2735, has demonstrated impressive results in a phase 2 trial.…

VKTX +0.3% todayRead at source ↗
● The Motley FoolNov 4, 2026 · 07:15 ET
Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.

The weight loss drug market is on track to reach nearly $100 billion by the end of the decade. Viking has a candidate, in two formulations, involved in phase 3 studies.…

VKTX +0.3% todayRead at source ↗
● PRNewsWireNov 3, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Viking Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders,…

VKTX +0.3% todayRead at source ↗
● The Motley FoolNov 2, 2026 · 07:22 ET
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.

UBS sees approximately 250% upside potential for Viking shares over the next year. Viking's weight loss candidates could compete effectively with the established drugs from Eli Lilly and Novo Nordisk.…

VKTX +0.3% todayRead at source ↗
● Zacks Investment ResearchOct 30, 2026 · 13:11 ET
VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?

Viking Therapeutics is set to target a potential first-half 2029 launch for VK2735, but clinical readouts, FDA review and intensifying competition could shape its timeline.…

VKTX +0.3% todayRead at source ↗
● Zacks Investment ResearchOct 30, 2026 · 10:31 ET
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's …

VKTX +0.3% todayRead at source ↗
● Seeking AlphaOct 29, 2026 · 16:13 ETEARNINGS EXPECTED BY FEB 16
Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet)

Viking Therapeutics, Inc. is advancing VK2735, a dual GLP-1/GIP agonist, targeting the obesity and diabetes market dominated by Eli Lilly and Novo Nordisk. VKTX's Phase 3 VANQUISH trials for injectable VK2735, and SUNRIS…

VKTX +0.3% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 13:56 ETEARNINGS EXPECTED BY FEB 16
VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses

Viking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.…

VKTX +0.3% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 11:02 ETEARNINGS EXPECTED BY FEB 16
VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress

Viking Therapeutics advances its Phase III obesity trials, reports promising VK2735 maintenance data and strengthens its cash position despite widening losses.…

VKTX +0.3% todayRead at source ↗
● 24/7 Wall StreetOct 29, 2026 · 10:03 ETEARNINGS EXPECTED BY FEB 16
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases

Eli Lilly (NYSE:LLY | LLY Price Prediction) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the glucagon-like peptide-1 (GLP-1…

VKTX +0.3% todayRead at source ↗
● Seeking AlphaOct 29, 2026 · 07:30 ET
Viking Therapeutics: Why A Successful Maintenance Readout Couldn't Save The Stock

Viking Therapeutics' maintenance data met upside criteria but failed to excite the market, with shares dropping post-release and dilution ongoing. VKTX is clearly pursuing a standalone strategy, ramping OpEx and infrastr…

VKTX +0.3% todayRead at source ↗
● MarketBeatOct 29, 2026 · 02:05 ETEARNINGS EXPECTED BY FEB 16
Viking Therapeutics Q3 Earnings Call Highlights

Viking Therapeutics NASDAQ: VKTX reported a wider third-quarter loss as it increased spending on late-stage obesity programs, while advancing phase III studies of both injectable and oral versions of its lead candidate, …

VKTX +0.3% todayRead at source ↗
● Seeking AlphaOct 28, 2026 · 20:50 ETEARNINGS EXPECTED BY FEB 16
Viking Therapeutics, Inc. (VKTX) Q3 2026 Earnings Call Transcript

Viking Therapeutics, Inc. (VKTX) Q3 2026 Earnings Call Transcript…

VKTX +0.3% todayRead at source ↗
● PRNewsWireOct 28, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

--   VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance -- -- SUNRISE Phase 3 Trials for Oral VK2735 Initiated -- -- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study; Pa…

VKTX +0.3% todayRead at source ↗
● Zacks Investment ResearchOct 26, 2026 · 11:06 ETEARNINGS EXPECTED BY FEB 16
Should You Buy Viking Therapeutics Stock Ahead of Q3 Results?

VKTX is likely to report Q3 results Oct. 28 as investors await updates on VK2735's oral and injectable obesity programs and 2027 data readouts.…

VKTX +0.3% todayRead at source ↗
● PRNewsWireOct 21, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026

Conference Call Scheduled for Wednesday, October 28, at 4:30 p.m. Eastern Time  SAN DIEGO, Oct. 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company foc…

VKTX +0.3% todayRead at source ↗
● PRNewsWireOct 14, 2026 · 07:05 ETCOMPANY'S OWN WORDS
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity

SUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes  SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biop…

VKTX +0.3% todayRead at source ↗
● PRNewsWireOct 6, 2026 · 07:05 ETCOMPANY'S OWN WORDS
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735 Monthly and Every-Other-Week Subcutaneous Regimens to also be Evaluated SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Vik…

VKTX +0.3% todayRead at source ↗
● PRNewsWireSep 28, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes

Gross Proceeds to Viking Approximately $575 Million SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel thera…

VKTX +0.3% todayRead at source ↗
● PRNewsWireSep 28, 2026 · 11:12 ET
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary du…

VKTX +0.3% todayRead at source ↗
● PRNewsWireSep 24, 2026 · 07:05 ETCOMPANY'S OWN WORDS
Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes

SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today an…

VKTX +0.3% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just VKTX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.